Search

George R Siber

from New York, NY
Age ~80

George Siber Phones & Addresses

  • 2000 Broadway, New York, NY 10023 (212) 595-6845
  • 2000 Broadway #2B, New York, NY 10023 (212) 595-6845
  • 2000 Broadway #PH2B, New York, NY 10023 (212) 595-6845
  • 160 W 66Th St #31G, New York, NY 10023
  • 160 66Th St, Manhattan, NY 10023 (212) 595-6845
  • Saugerties, NY
  • Otisfield, ME
  • 37 Corey Rd, Brookline, MA 02445
  • 18 Barney Park, Irvington, NY 10533 (914) 591-6822 (914) 591-9136
  • Cambridge, MA
  • 18 Barney Park, Irvington, NY 10533 (914) 374-2087

Work

Company: Clearsite antibodies Jul 2019 Position: Co-founder and director

Education

School / High School: Harvard Medical School 1973 to 1975

Skills

Vaccines • Infectious Diseases • Biotechnology • Cell • Biopharmaceuticals • Monoclonal Antibodies • R&D • Immunology • Life Sciences • Clinical Trials • Molecular Biology • Pharmaceutical Industry • Lifesciences • Technology Transfer • Chromatography • Clinical Development • Elisa • Drug Discovery • Cell Culture • Clinical Research • Laboratory • Flow Cytometry • Antibodies • Biochemistry • Cancer • Fda • Drug Development • Protein Chemistry • Validation • Hplc • Microbiology • Oncology • Cell Biology • Virology • Commercialization • Purification • Gmp • Internal Medicine • Pharmacology • Medicine • Assay Development • Genomics • Pcr • Genetics • Regulatory Affairs • Hardware Diagnostics • Glp • Vaccine R&D

Languages

English • German • French

Interests

Nyc • Skiing • Outdoors • Chinese Antiques • Building Stuff

Emails

Industries

Biotechnology

Resumes

Resumes

George Siber Photo 1

Co-Founder And Member Of Bod

View page
Location:
New York, NY
Industry:
Biotechnology
Work:
Clearsite Antibodies
Co-Founder and Director

Iliad Biotechnologies
Member of Sab

Paxvax, Inc. 2014 - Sep 2018
Member of Sab

Advaccine 2014 - Sep 2018
Member of Sab

Aditec Vaccine Consortium Jan 2012 - Dec 2016
Member of Scientific Advisory Committee
Education:
Harvard Medical School 1973 - 1975
Harvard Medical School 1972 - 1973
Rush Medical College of Rush University Medical Center 1970 - 1972
Mcgill University 1966 - 1970
Doctor of Medicine, Doctorates
Bishop's University 1962 - 1966
Bachelors, Bachelor of Science, Biology
Skills:
Vaccines
Infectious Diseases
Biotechnology
Cell
Biopharmaceuticals
Monoclonal Antibodies
R&D
Immunology
Life Sciences
Clinical Trials
Molecular Biology
Pharmaceutical Industry
Lifesciences
Technology Transfer
Chromatography
Clinical Development
Elisa
Drug Discovery
Cell Culture
Clinical Research
Laboratory
Flow Cytometry
Antibodies
Biochemistry
Cancer
Fda
Drug Development
Protein Chemistry
Validation
Hplc
Microbiology
Oncology
Cell Biology
Virology
Commercialization
Purification
Gmp
Internal Medicine
Pharmacology
Medicine
Assay Development
Genomics
Pcr
Genetics
Regulatory Affairs
Hardware Diagnostics
Glp
Vaccine R&D
Interests:
Nyc
Skiing
Outdoors
Chinese Antiques
Building Stuff
Languages:
English
German
French

Publications

Us Patents

Lipopolysaccharide-Binding And Neutralizing Peptides

View page
US Patent:
6384188, May 7, 2002
Filed:
Jun 7, 1995
Appl. No.:
08/477778
Inventors:
Adolf Hoess - Warngau, DE
Robert C. Liddington - Boston MA
George R. Siber - Irvington NY
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C07K 1700
US Classification:
530326, 530327, 530328, 530811, 530812, 530814, 530815, 530817, 514 2, 514 13
Abstract:
Substance which bind with high affinity to endotoxin (lipopolysaccharide [LPS]), and which are useful for the prevention or treatment of, for example, Gram-negative and Gram-positive bacterial sepsis, and for the treatment of bacterial and fungal infections as well as for neutralizing effects associated with heparin. The substances are LPS-binding peptides comprising an LPS-binding domain. DNA sequences encoding peptides, recombinant microorganisms containing the DNA, pharmaceutical compositions containing the peptides of the invention, and diagnostic kits. Methods for the detection and removal of bacterial LPS from solutions.

Herpesvirus Replication Defective Mutants

View page
US Patent:
7223411, May 29, 2007
Filed:
Jul 21, 1994
Appl. No.:
08/278601
Inventors:
David Knipe - Auburndale MA, US
Robert Finberg - Canton MA, US
George Siber - Brookline MA, US
Assignee:
Dana-Farber Cancer Institute - Boston MA
President & Fellows of Harvard College - Cambridge MA
International Classification:
A61K 39/245
US Classification:
4242291, 4241991, 4353201
Abstract:
A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.

Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition

View page
US Patent:
7709001, May 4, 2010
Filed:
Dec 22, 2006
Appl. No.:
11/644924
Inventors:
William P. Hausdorff - Woluwe-Saint-Lambert, BE
George Rainer Siber - New York NY, US
Peter R. Paradiso - Valley Forge PA, US
A. Krishna Prasad - Chapel Hill NC, US
Assignee:
Wyeth LLC - Madison NJ
International Classification:
A61K 39/00
US Classification:
4241841
Abstract:
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising serotype 3 polysaccharide covalently linked to a carrier protein, the method including periodic acid oxidation of the polysaccharide in the presence of bivalent cations.

Compositions And Methods For Treatment Of Severe Acute Respiratory Syndrome (Sars)

View page
US Patent:
7722886, May 25, 2010
Filed:
May 20, 2004
Appl. No.:
10/557479
Inventors:
George R. Siber - Irvington NY, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 39/215
A61K 39/395
C12P 19/34
C07H 19/00
US Classification:
4242211, 4241451, 435335, 435 912, 536 221
Abstract:
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

Methods For Treatment Of Severe Acute Respiratory Syndrome (Sars)

View page
US Patent:
7892563, Feb 22, 2011
Filed:
May 20, 2003
Appl. No.:
10/441059
Inventors:
George R. Siber - Irvington NY, US
Assignee:
Wyeth Holdings Corporation - Madison NJ
International Classification:
A61K 39/215
A61K 39/395
US Classification:
4242211, 4241451, 435335
Abstract:
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

Vaccines Against Herpes Simplex Virus Type 2: Compositions And Methods For Eliciting An Immune Response

View page
US Patent:
8617564, Dec 31, 2013
Filed:
May 24, 2010
Appl. No.:
12/786425
Inventors:
Deborah Long - Monroe NY, US
Jessica Flechtner - Maynard MA, US
Mojca Skoberne - Cambridge MA, US
George R. Siber - New York NY, US
Assignee:
Genocea Biosciences, Inc. - Cambridge MA
International Classification:
A61K 39/245
US Classification:
4241861, 4242311
Abstract:
Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.

Herpesvirus Replication Defective Mutants

View page
US Patent:
20020009462, Jan 24, 2002
Filed:
Jul 31, 1997
Appl. No.:
08/903830
Inventors:
DAVID M. KNIPE - AUBURNDALE MA, US
ROBERT FINBERG - CANTON MA, US
GEORGE SIBER - BROOKLINE MA, US
International Classification:
A61K039/12
US Classification:
424/199100
Abstract:
A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.

Herpevirus Replication Defective Mutants

View page
US Patent:
20020086035, Jul 4, 2002
Filed:
Mar 4, 1998
Appl. No.:
09/034464
Inventors:
DAVID M. KNIPE - AUBURNDALE MA, US
ROBERT FINBERG - CANTON MA, US
GEORGE SIBER - BROOKLINE MA, US
International Classification:
A61K039/245
A61K039/12
A61K039/02
US Classification:
424/231100, 424/235100, 424/199100
Abstract:
A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.
George R Siber from New York, NY, age ~80 Get Report